Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Chemical synthesis"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 389
Tytuł:
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.
Autorzy:
Boby ML; Pharmacology Graduate Program, Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA.; Program in Chemical Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.; Program in Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Fearon D; Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot, UK.
Ferla M; Oxford Biomedical Research Centre, National Institute for Health Research, University of Oxford, Oxford, UK.
Filep M; Department of Chemical and Structural Biology, The Weizmann Institute of Science, Rehovot, Israel.
Koekemoer L; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Robinson MC; PostEra Inc., Cambridge, MA 02142, USA.
Chodera JD; Program in Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Lee AA; PostEra Inc., Cambridge, MA 02142, USA.
London N; Department of Chemical and Structural Biology, The Weizmann Institute of Science, Rehovot, Israel.
von Delft A; Oxford Biomedical Research Centre, National Institute for Health Research, University of Oxford, Oxford, UK.; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
von Delft F; Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot, UK.; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Department of Biochemistry, University of Johannesburg, Auckland Park, Johannesburg 2006, South Africa.
Achdout H; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Aimon A; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Alonzi DS; University of Oxford, Department of Biochemistry, Oxford Glycobiology Institute, South Parks Road, Oxford OX1 3QU, UK.
Arbon R; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.
Aschenbrenner JC; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Balcomb BH; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Bar-David E; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Barr H; The Weizmann Institute of Science, Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Rehovot, 7610001, Israel.
Ben-Shmuel A; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Bennett J; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.; University of Oxford, Nuffield Department of Medicine, Target Discovery Institute, Oxford, OX3 7FZ, UK.
Bilenko VA; Enamine Ltd, Kyiv, 02094, Ukraine.; Taras Shevchenko National University of Kyiv, Kyiv, 01601, Ukraine.
Borden B; .
Boulet P; Drugs for Neglected Diseases Initiative (DNDi), Geneva, 1202, Switzerland.
Bowman GR; University of Pennsylvania, Departments of Biochemistry and Biophysics and Bioengineering, Philadelphia, PA 19083, USA.
Brewitz L; University of Oxford, Department of Chemistry, Chemistry Research Laboratory, Oxford, OX1 3TA, UK.
Brun J; University of Oxford, Department of Biochemistry, Oxford Glycobiology Institute, South Parks Road, Oxford OX1 3QU, UK.
Bvnbs S; Sai Life Sciences Limited, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India.
Calmiano M; UCB, Slough, SL1 3WE, UK.
Carbery A; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; University of Oxford, Department of Statistics, Oxford OX1 3LB, UK.
Carney DW; Takeda Development Center Americas, Inc., San Diego, CA 92121, USA.
Cattermole E; University of Oxford, Department of Biochemistry, Oxford Glycobiology Institute, South Parks Road, Oxford OX1 3QU, UK.
Chang E; Takeda Development Center Americas, Inc., San Diego, CA 92121, USA.
Chernyshenko E; Enamine Ltd, Kyiv, 02094, Ukraine.
Clyde A; Argonne National Lab, Lemont, IL 60439, USA.
Coffland JE; Cauldron Development Oy, Helsinki, 00140, Finland.
Cohen G; The Weizmann Institute of Science, Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Rehovot, 7610001, Israel.
Cole JC; Cambridge Crystallographic Data Centre, Cambridge, CB2 1EZ, UK.
Contini A; University of Milan, Department of General and Organic Chemistry, Milan, 20133, Italy.
Cox L; Life Compass Consulting Ltd, Macclesfield, SK10 5UE, UK.
Croll TI; The University of Cambridge, Cambridge Institute for Medical Research, Department of Haematology, Cambridge CB2 0XY, UK.; Present address: Altos Labs, BioML group, Great Abington, CB21 6GP.
Cvitkovic M; PostEra Inc., Cambridge, MA, 02142, USA.
De Jonghe S; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Dias A; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Donckers K; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Dotson DL; Datryllic LLC, Phoenix AZ, 85003, USA.
Douangamath A; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Duberstein S; The Weizmann Institute of Science, Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Rehovot, 7610001, Israel.
Dudgeon T; Informatics Matters Ltd, Bicester, OX26 6JU, UK.
Dunnett LE; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Eastman P; Stanford University, Department of Chemistry, Stanford, CA 94305, USA.
Erez N; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Eyermann CJ; Northeastern University, Department of Chemistry and Chemical Biology, Boston MA 02115, USA.
Fairhead M; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.
Fate G; Thames Pharma Partners LLC, Mystic, CT 06355, USA.
Fedorov O; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.; University of Oxford, Nuffield Department of Medicine, Target Discovery Institute, Oxford, OX3 7FZ, UK.
Fernandes RS; University of Sao Paulo, Sao Carlos Institute of Physics, Sao Carlos, 13563-120, Brazil.
Ferrins L; Northeastern University, Department of Chemistry and Chemical Biology, Boston MA 02115, USA.
Foster R; University of Leeds, School of Chemistry, Leeds, LS2 9JT, UK.
Foster H; University of Leeds, School of Chemistry, Leeds, LS2 9JT, UK.; Present address: Exscientia, Oxford Science Park, Oxford, OX4 4GE, UK.
Fraisse L; Drugs for Neglected Diseases Initiative (DNDi), Geneva, 1202, Switzerland.
Gabizon R; The Weizmann Institute of Science, Department of Chemical and Structural Biology, Rehovot, 7610001, Israel.
García-Sastre A; Icahn School of Medicine at Mount Sinai, Department of Microbiology, New York, NY 10029, USA.; Icahn School of Medicine at Mount Sinai, Global Health and Emerging Pathogens Institute, New York, NY 10029, USA.; Icahn School of Medicine at Mount Sinai, Department of Medicine, Division of Infectious Diseases, New York, NY 10029, USA.; Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY 10029, USA.; Icahn School of Medicine at Mount Sinai, Department of Pathology, Molecular and Cell-Based Medicine, New York, NY 10029, USA.
Gawriljuk VO; University of Sao Paulo, Sao Carlos Institute of Physics, Sao Carlos, 13563-120, Brazil.; Present address: University of Groningen, Groningen Research Institute of Pharmacy, Department of Drug Design, Groningen, 9700 AV, Netherlands.
Gehrtz P; The Weizmann Institute of Science, Department of Chemical and Structural Biology, Rehovot, 7610001, Israel.; Present address: Merck Healthcare KGaA, Darmstadt, 64293, Germany.
Gileadi C; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.
Giroud C; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.; University of Oxford, Nuffield Department of Medicine, Target Discovery Institute, Oxford, OX3 7FZ, UK.
Glass WG; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.; Present address: Exscientia, Oxford Science Park, Oxford, OX4 4GE, UK.
Glen RC; University of Cambridge, Department of Chemistry, Cambridge, CB2 1EW, UK.
Glinert I; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Godoy AS; University of Sao Paulo, Sao Carlos Institute of Physics, Sao Carlos, 13563-120, Brazil.
Gorichko M; Taras Shevchenko National University of Kyiv, Kyiv, 01601, Ukraine.
Gorrie-Stone T; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Griffen EJ; MedChemica Ltd, Macclesfield, Cheshire. SK11 6PU UK.
Haneef A; Illinois Institute of Technology, Department of Biology, Chicago IL 60616 USA.
Hassell Hart S; University of Sussex, Department of Chemistry, School of Life Sciences, Brighton, East Sussex, BN1 9QJ, UK.
Heer J; Syngene International Limited, Headington, Oxford, OX3 7BZ, UK.
Henry M; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.
Hill M; University of Oxford, Department of Biochemistry, Oxford Glycobiology Institute, South Parks Road, Oxford OX1 3QU, UK.; Present address: Sir William Dunn School of Pathology, Oxford. OX1 3RE, UK.
Horrell S; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Huang QYJ; University of Massachusetts, Chan Medical School, Department of Biochemistry and Molecular Biotechnology, Worcester MA 01655, USA.
Huliak VD; Enamine Ltd, Kyiv, 02094, Ukraine.
Hurley MFD; Temple University, Department of Chemistry, Philadelphia, PA 19122, USA.
Israely T; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Jajack A; PostEra Inc., Cambridge, MA, 02142, USA.
Jansen J; RWTH Aachen University, Institute of Experimental Medicine and Systems Biology, Aachen, 52074, Germany.
Jnoff E; UCB, Chemin du Foriest, 1420 Braine-l'Alleud, Belgium.
Jochmans D; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
John T; University of Oxford, Department of Chemistry, Chemistry Research Laboratory, Oxford, OX1 3TA, UK.; Present address: AMSilk, Neuried, 82061, Germany.
Kaminow B; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Tri-Institutional Program in Computational Biology and Medicine, New York, NY 10065, USA.
Kang L; Illinois Institute of Technology, Department of Applied Mathematics, Chicago IL 60616 USA.
Kantsadi AL; University of Oxford, Department of Biochemistry, Oxford Glycobiology Institute, South Parks Road, Oxford OX1 3QU, UK.; University of Thessaly, Department of Biochemistry and Biotechnology, Larissa, 415 00, Greece.
Kenny PW; Berwick-on-Sea, North Coast Road, Blanchisseuse, Saint George, Trinidad and Tobago.
Kiappes JL; University of Oxford, Department of Biochemistry, Oxford Glycobiology Institute, South Parks Road, Oxford OX1 3QU, UK.; Present address: University College of London, Department of Chemistry, London WC1H 0AJ, UK.
Kinakh SO; Enamine Ltd, Kyiv, 02094, Ukraine.
Kovar B; M2M solutions s.r.o. Žilina, 010 01, Slovakia.
Krojer T; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.; MAX IV Laboratory, Fotongatan 2, 224 84 Lund, Sweden.
La VNT; Illinois Institute of Technology, Department of Biology, Chicago IL 60616 USA.
Laghnimi-Hahn S; Drugs for Neglected Diseases Initiative (DNDi), Geneva, 1202, Switzerland.
Lefker BA; Thames Pharma Partners LLC, Mystic, CT 06355, USA.
Levy H; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Lithgo RM; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Logvinenko IG; Enamine Ltd, Kyiv, 02094, Ukraine.
Lukacik P; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Macdonald HB; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.; Present address: Charm Therapeutics, London, N1C 4AG, UK.
MacLean EM; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.
Makower LL; University of Oxford, Department of Biochemistry, Oxford Glycobiology Institute, South Parks Road, Oxford OX1 3QU, UK.
Malla TR; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.
Marples PG; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Matviiuk T; Enamine Ltd, Kyiv, 02094, Ukraine.
McCorkindale W; Present address: Charm Therapeutics, London, N1C 4AG, UK.; University of Cambridge, Cavendish Laboratory, Cambridge, CB3 0HE UK.
McGovern BL; Icahn School of Medicine at Mount Sinai, Department of Microbiology, New York, NY 10029, USA.; Icahn School of Medicine at Mount Sinai, Global Health and Emerging Pathogens Institute, New York, NY 10029, USA.
Melamed S; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Melnykov KP; Enamine Ltd, Kyiv, 02094, Ukraine.; Taras Shevchenko National University of Kyiv, Kyiv, 01601, Ukraine.
Michurin O; Enamine Ltd, Kyiv, 02094, Ukraine.
Miesen P; Radboud University Medical Center, Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Nijmegen, 6525 GA, Netherlands.
Mikolajek H; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Milne BF; University of Aberdeen, Department of Chemistry, Old Aberdeen, AB24 3UE Scotland, UK.; University of Coimbra, CFisUC, Department of Physics, Coimbra, 3004-516, Portugal.
Minh D; Illinois Institute of Technology, Department of Chemistry, Chicago IL 60616 USA.
Morris A; PostEra Inc., Cambridge, MA, 02142, USA.
Morris GM; University of Oxford, Department of Statistics, Oxford OX1 3LB, UK.
Morwitzer MJ; University of Nebraska Medical Centre, Dept of Pathology and Microbiology, Omaha, NE 68198-5900, USA.
Moustakas D; Relay Therapeutics, Cambridge, MA 02139, USA.
Mowbray CE; Drugs for Neglected Diseases Initiative (DNDi), Geneva, 1202, Switzerland.
Nakamura AM; University of Sao Paulo, Sao Carlos Institute of Physics, Sao Carlos, 13563-120, Brazil.; Present address: Instituto Butantan, Sao Paulo, 05503-900, Brazil.
Neto JB; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Neyts J; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Nguyen L; PostEra Inc., Cambridge, MA, 02142, USA.
Noske GD; University of Sao Paulo, Sao Carlos Institute of Physics, Sao Carlos, 13563-120, Brazil.
Oleinikovas V; UCB, Slough, SL1 3WE, UK.; Present address: Monte Rosa Therapeutics, Basel, CH 4057, Switzerland.
Oliva G; University of Sao Paulo, Sao Carlos Institute of Physics, Sao Carlos, 13563-120, Brazil.
Overheul GJ; Radboud University Medical Center, Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Nijmegen, 6525 GA, Netherlands.
Owen CD; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Pai R; PostEra Inc., Cambridge, MA, 02142, USA.
Pan J; PostEra Inc., Cambridge, MA, 02142, USA.
Paran N; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Payne AM; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Tri-Institutional Program in Computational Biology and Medicine, New York, NY 10065, USA.
Perry B; Drugs for Neglected Diseases Initiative (DNDi), Geneva, 1202, Switzerland.; Present address: Medicxi, Geneva, 1204, Switzerland.
Pingle M; Sai Life Sciences Limited, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India.
Pinjari J; Sai Life Sciences Limited, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India.; Present address: Sun Pharma Advanced Research Company (SPARC), Baroda, India.
Politi B; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Powell A; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Pšenák V; M2M solutions s.r.o. Žilina, 010 01, Slovakia.
Pulido I; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.
Puni R; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Rangel VL; University of São Paulo, Ribeirão Preto School of Pharmaceutical Sciences, Ribeirão Preto - SP/CEP 14040-903, Brazil.; Present address: Evotec (UK) Ltd, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK.
Reddi RN; The Weizmann Institute of Science, Department of Chemical and Structural Biology, Rehovot, 7610001, Israel.
Rees P; Compass Bussiness Partners Ltd, Southcliffe, Bucks, SL9 0PD, UK.
Reid SP; University of Nebraska Medical Centre, Dept of Pathology and Microbiology, Omaha, NE 68198-5900, USA.
Reid L; MedChemica Ltd, Macclesfield, Cheshire. SK11 6PU UK.
Resnick E; The Weizmann Institute of Science, Department of Chemical and Structural Biology, Rehovot, 7610001, Israel.
Ripka EG; PostEra Inc., Cambridge, MA, 02142, USA.
Robinson RP; Thames Pharma Partners LLC, Mystic, CT 06355, USA.
Rodriguez-Guerra J; Charité - Universitätsmedizin Berlin, In silico Toxicology and Structural Bioinformatics, Berlin, 10117, Germany.
Rosales R; Icahn School of Medicine at Mount Sinai, Department of Microbiology, New York, NY 10029, USA.; Icahn School of Medicine at Mount Sinai, Global Health and Emerging Pathogens Institute, New York, NY 10029, USA.
Rufa DA; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Tri-Institutional Program in Computational Biology and Medicine, New York, NY 10065, USA.
Saar K; University of Cambridge, Cavendish Laboratory, Cambridge, CB3 0HE UK.
Saikatendu KS; Takeda Development Center Americas, Inc., San Diego, CA 92121, USA.
Salah E; University of Oxford, Department of Chemistry, Chemistry Research Laboratory, Oxford, OX1 3TA, UK.
Schaller D; Charité - Universitätsmedizin Berlin, In silico Toxicology and Structural Bioinformatics, Berlin, 10117, Germany.
Scheen J; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.
Schiffer CA; University of Massachusetts, Chan Medical School, Department of Biochemistry and Molecular Biotechnology, Worcester MA 01655, USA.
Schofield CJ; University of Oxford, Department of Chemistry, Chemistry Research Laboratory, Oxford, OX1 3TA, UK.
Shafeev M; Enamine Ltd, Kyiv, 02094, Ukraine.
Shaikh A; Sai Life Sciences Limited, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India.
Shaqra AM; University of Massachusetts, Chan Medical School, Department of Biochemistry and Molecular Biotechnology, Worcester MA 01655, USA.
Shi J; UCB, Chemin du Foriest, 1420 Braine-l'Alleud, Belgium.; Present address: Eli Lilly and Company, San Diego, CA 92121, USA.
Shurrush K; The Weizmann Institute of Science, Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Rehovot, 7610001, Israel.
Singh S; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.
Sittner A; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Sjö P; Drugs for Neglected Diseases Initiative (DNDi), Geneva, 1202, Switzerland.
Skyner R; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Smalley A; UCB, Slough, SL1 3WE, UK.
Smeets B; Radboud University Medical Center, Department of pathology, Radboud Institute for Molecular Life Sciences, Nijmegen, 6525 GA, Netherlands.
Smilova MD; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.
Solmesky LJ; The Weizmann Institute of Science, Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Rehovot, 7610001, Israel.
Spencer J; University of Sussex, Department of Chemistry, School of Life Sciences, Brighton, East Sussex, BN1 9QJ, UK.
Strain-Damerell C; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Swamy V; Sai Life Sciences Limited, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078, Telangana, India.; Present address: TCG Life Sciences, Pune, India.
Tamir H; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Taylor JC; University of Oxford, Nuffield Department of Medicine, Wellcome Centre for Human Genetics, Oxford OX3 7BN, UK.
Tennant RE; Lhasa Limited, Leeds, LS11 5PS, UK.
Thompson W; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Thompson A; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.; Present address: Walter and Eliza Hall Institute, Parkville 3052, Victoria, Australia.
Tomásio S; Collaborative Drug Discovery, Cambridge, CB2 1GE, UK.
Tomlinson CWE; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Tsurupa IS; Enamine Ltd, Kyiv, 02094, Ukraine.
Tumber A; University of Oxford, Department of Chemistry, Chemistry Research Laboratory, Oxford, OX1 3TA, UK.
Vakonakis I; University of Oxford, Department of Biochemistry, Oxford Glycobiology Institute, South Parks Road, Oxford OX1 3QU, UK.; Present address: Lonza Biologics, Lonza Ltd, Lonzastrasse, CH-3930 Visp, Switzerland.
van Rij RP; Radboud University Medical Center, Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Nijmegen, 6525 GA, Netherlands.
Vangeel L; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Varghese FS; Radboud University Medical Center, Department of Medical Microbiology, Radboud Institute for Molecular Life Sciences, Nijmegen, 6525 GA, Netherlands.; Present address: uniQure Biopharma, Amsterdam, 1105 BP, Netherlands.
Vaschetto M; Collaborative Drug Discovery, Cambridge, CB2 1GE, UK.
Vitner EB; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Voelz V; Temple University, Department of Chemistry, Philadelphia, PA 19122, USA.
Volkamer A; Charité - Universitätsmedizin Berlin, In silico Toxicology and Structural Bioinformatics, Berlin, 10117, Germany.; Present address: Saarland University, Data Driven Drug Design, Campus - E2.1, 66123 Saarbrücken, Germany.
Walsh MA; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Ward W; Walter Ward Consultancy and Training, Derbyshire, SK22 4AA, UK.
Weatherall C; Collaborative Drug Discovery, Burlingame, CA 94010, USA.
Weiss S; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
White KM; Icahn School of Medicine at Mount Sinai, Department of Microbiology, New York, NY 10029, USA.; Icahn School of Medicine at Mount Sinai, Global Health and Emerging Pathogens Institute, New York, NY 10029, USA.
Wild CF; Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, OX11 0DE, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK.
Witt KD; University of Oxford, Nuffield Department of Medicine, Pandemic Sciences Institute, Oxford, Oxon, OX3 7DQ, UK.
Wittmann M; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.
Wright N; University of Oxford, Nuffield Department of Medicine, Centre for Medicines Discovery, Oxford, OX3 7DQ, UK.
Yahalom-Ronen Y; Israel Institute for Biological Research, Department of Infectious Diseases, Ness-Ziona, Israel.
Yilmaz NK; University of Massachusetts, Chan Medical School, Department of Biochemistry and Molecular Biotechnology, Worcester MA 01655, USA.
Zaidmann D; The Weizmann Institute of Science, Department of Chemical and Structural Biology, Rehovot, 7610001, Israel.
Zhang I; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Computational and Systems Biology Program, New York, NY 10065, USA.
Zidane H; The Weizmann Institute of Science, Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Rehovot, 7610001, Israel.
Zitzmann N; University of Oxford, Department of Biochemistry, Oxford Glycobiology Institute, South Parks Road, Oxford OX1 3QU, UK.
Zvornicanin SN; University of Massachusetts, Chan Medical School, Department of Biochemistry and Molecular Biotechnology, Worcester MA 01655, USA.
Pokaż więcej
Corporate Authors:
COVID Moonshot Consortium‡
Źródło:
Science (New York, N.Y.) [Science] 2023 Nov 10; Vol. 382 (6671), pp. eabo7201. Date of Electronic Publication: 2023 Nov 10.
Typ publikacji:
Journal Article
MeSH Terms:
Coronavirus 3C Proteases*/antagonists & inhibitors
Coronavirus 3C Proteases*/chemistry
SARS-CoV-2*
Drug Discovery*
Coronavirus Protease Inhibitors*/chemical synthesis
Coronavirus Protease Inhibitors*/chemistry
Coronavirus Protease Inhibitors*/pharmacology
COVID-19 Drug Treatment*
Humans ; Molecular Docking Simulation ; Structure-Activity Relationship ; Crystallography, X-Ray
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Abiotic peptides as carriers of information for the encoding of small-molecule library synthesis.
Autorzy:
Rössler SL; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Grob NM; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Buchwald SL; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Pentelute BL; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.; Center for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2023 Mar 03; Vol. 379 (6635), pp. 939-945. Date of Electronic Publication: 2023 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Peptide Library*
Peptides*/chemical synthesis
Peptides*/chemistry
Small Molecule Libraries*/chemical synthesis
Small Molecule Libraries*/chemistry
Drug Discovery*
Ligands ; Nuclear Proteins/chemistry ; Nuclear Proteins/genetics ; Transcription Factors/chemistry ; Transcription Factors/genetics ; Protein Stability ; Carbonic Anhydrase IX
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Peptide barcodes meet drug discovery.
Autorzy:
Haap W; Research and Development Division, F. Hoffmann-La Roche AG, Basel, Switzerland.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2023 Mar 03; Vol. 379 (6635), pp. 883. Date of Electronic Publication: 2023 Mar 02.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Peptides*/chemical synthesis
Peptides*/chemistry
Peptides*/therapeutic use
Small Molecule Libraries*/chemical synthesis
Small Molecule Libraries*/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Antibiotics made to order.
Autorzy:
Seipke RF; Faculty of Biological Sciences, Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 May 27; Vol. 376 (6596), pp. 919-920. Date of Electronic Publication: 2022 May 26.
Typ publikacji:
Journal Article; Comment
MeSH Terms:
Anti-Bacterial Agents*/chemical synthesis
Anti-Bacterial Agents*/chemistry
Anti-Bacterial Agents*/pharmacology
Drug Discovery*/methods
Drug Resistance, Multiple, Bacterial*/drug effects
Drug Resistance, Multiple, Bacterial*/genetics
Lipopeptides*/chemical synthesis
Lipopeptides*/chemistry
Lipopeptides*/pharmacology
Animals ; Humans ; Multigene Family
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery of triterpenoids as potent dual inhibitors of pancreatic lipase and human carboxylesterase 1.
Autorzy:
Zhang J; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Pan QS; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Qian XK; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.; Translational Medicine Research Center, Guizhou Medical University, Guizhou, China.
Zhou XL; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wang YJ; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
He RJ; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wang LT; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Li YR; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Huo H; Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
Sun CG; The Second Hospital of Dalian Medical University, Dalian, China.
Sun L; The Second Hospital of Dalian Medical University, Dalian, China.
Zou LW; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yang L; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 629-640.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Carboxylic Ester Hydrolases/*antagonists & inhibitors
Enzyme Inhibitors/*pharmacology
Lipase/*antagonists & inhibitors
Pancreas/*enzymology
Triterpenes/*pharmacology
Carboxylic Ester Hydrolases/metabolism ; Dose-Response Relationship, Drug ; Enzyme Inhibitors/chemical synthesis ; Enzyme Inhibitors/chemistry ; Humans ; Lipase/metabolism ; Molecular Structure ; Structure-Activity Relationship ; Triterpenes/chemical synthesis ; Triterpenes/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Diversely substituted sulfamides for fragment-based drug discovery of carbonic anhydrase inhibitors: synthesis and inhibitory profile.
Autorzy:
Sharonova T; Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia.
Zhmurov P; Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia.
Kalinin S; Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia.
Nocentini A; Neurofarba Department, Universita Degli Studi di Firenze, Florence, Italy.
Angeli A; Neurofarba Department, Universita Degli Studi di Firenze, Florence, Italy.
Ferraroni M; Neurofarba Department, Universita Degli Studi di Firenze, Florence, Italy.
Korsakov M; Pharmaceutical Technology Transfer Center, Ushinsky Yaroslavl State Pedagogical University, Yaroslavl, Russia.
Supuran CT; Neurofarba Department, Universita Degli Studi di Firenze, Florence, Italy.
Krasavin M; Institute of Chemistry, Saint Petersburg State University, Saint Petersburg, Russia.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 857-865.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Carbonic Anhydrase Inhibitors/*pharmacology
Carbonic Anhydrases/*metabolism
Sulfonamides/*pharmacology
Carbonic Anhydrase Inhibitors/chemical synthesis ; Carbonic Anhydrase Inhibitors/chemistry ; Dose-Response Relationship, Drug ; Humans ; Isoenzymes/antagonists & inhibitors ; Isoenzymes/metabolism ; Molecular Structure ; Structure-Activity Relationship ; Sulfonamides/chemical synthesis ; Sulfonamides/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms.
Autorzy:
Eldehna WM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
Taghour MS; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Al-Warhi T; Department of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Nocentini A; Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, Italy.
Elbadawi MM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
Mahdy HA; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Abdelrahman MA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt.
Alotaibi OJ; Department of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Aljaeed N; Department of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Elimam DM; Department of Pharmacognosy, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom.
Afarinkia K; Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom.
Abdel-Aziz HA; Department of Applied Organic Chemistry, National Research Center, Giza, Egypt.
Supuran CT; Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, Italy.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 531-541.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Carbonic Anhydrase IX/*antagonists & inhibitors
Carbonic Anhydrase Inhibitors/*pharmacology
Carbonic Anhydrases/*metabolism
Coumarins/*pharmacology
Thiazolidinediones/*pharmacology
Antigens, Neoplasm/metabolism ; Apoptosis/drug effects ; Carbonic Anhydrase IX/metabolism ; Carbonic Anhydrase Inhibitors/chemical synthesis ; Carbonic Anhydrase Inhibitors/chemistry ; Cell Cycle/drug effects ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Coumarins/chemical synthesis ; Coumarins/chemistry ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; MCF-7 Cells ; Molecular Structure ; Structure-Activity Relationship ; Thiazolidinediones/chemical synthesis ; Thiazolidinediones/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Discovery of novel paeonol-based derivatives against skin inflammation in vitro and in vivo .
Autorzy:
Wu J; School of Pharmacy, Anhui Medical University, Hefei, P. R. China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, P. R. China.
Zhu R; School of Pharmacy, Anhui Medical University, Hefei, P. R. China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, P. R. China.
Cao GM; School of Pharmacy, Anhui Medical University, Hefei, P. R. China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, P. R. China.
Du JC; School of Pharmacy, Anhui Medical University, Hefei, P. R. China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, P. R. China.
Liu X; Department of Clinical Medicine, Second Clinical Medical College, Anhui Medical University, Hefei, P. R. China.
Diao LZ; School of Pharmacy, Anhui Medical University, Hefei, P. R. China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, P. R. China.
Zhang ZY; School of Pharmacy, Anhui Medical University, Hefei, P. R. China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, P. R. China.
Hu YS; School of Pharmacy, Anhui Medical University, Hefei, P. R. China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, P. R. China.; Department of Medicine, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, P. R. China.
Liu XH; School of Pharmacy, Anhui Medical University, Hefei, P. R. China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, P. R. China.
Shi JB; School of Pharmacy, Anhui Medical University, Hefei, P. R. China.; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, P. R. China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 817-831.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Acetophenones/*pharmacology
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
Inflammation/*drug therapy
Skin/*drug effects
Acetophenones/chemical synthesis ; Acetophenones/chemistry ; Animals ; Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis ; Anti-Inflammatory Agents, Non-Steroidal/chemistry ; Cell Line ; Cell Proliferation/drug effects ; Cells, Cultured ; Dose-Response Relationship, Drug ; Female ; Humans ; Inflammation/metabolism ; JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors ; JNK Mitogen-Activated Protein Kinases/metabolism ; Lipopolysaccharides/antagonists & inhibitors ; Lipopolysaccharides/pharmacology ; Mice ; Mice, Inbred BALB C ; Microsomes, Liver/chemistry ; Microsomes, Liver/metabolism ; Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors ; Mitogen-Activated Protein Kinase Kinases/metabolism ; Molecular Structure ; Nitric Oxide/antagonists & inhibitors ; Nitric Oxide/biosynthesis ; Signal Transduction/drug effects ; Skin/metabolism ; Structure-Activity Relationship ; p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors ; p38 Mitogen-Activated Protein Kinases/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The discovery of a novel series of potential ERRα inverse agonists based on p-nitrobenzenesulfonamide template for triple-negative breast cancer in vivo .
Autorzy:
Gao Z; School of Chemistry and Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, P. R. China.
Wang T; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Li R; School of Chemistry and Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, P. R. China.
Du Y; School of Chemistry and Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, P. R. China.
Lv H; School of Chemistry and Chemical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, P. R. China.
Zhang L; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Chen H; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Shi X; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Li Q; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, P. R. China.
Shen J; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P. R. China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 125-134.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Antineoplastic Agents/*pharmacology
Nitrobenzenes/*pharmacology
Receptors, Estrogen/*metabolism
Sulfonamides/*pharmacology
Triple Negative Breast Neoplasms/*drug therapy
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Female ; Humans ; Molecular Docking Simulation ; Molecular Structure ; Nitrobenzenes/chemical synthesis ; Nitrobenzenes/chemistry ; Structure-Activity Relationship ; Sulfonamides/chemical synthesis ; Sulfonamides/chemistry ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/pathology ; ERRalpha Estrogen-Related Receptor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Design of Novel 4-Aminobenzofuroxans and Evaluation of Their Antimicrobial and Anticancer Activity.
Autorzy:
Chugunova E; Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Tatarstan 420088, Russia.; Laboratory of Plant Infectious Diseases, FRC Kazan Scientific Center of Russian Academy of Sciences, Kazan, Tatarstan 420111, Russia.
Gazizov A; Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Tatarstan 420088, Russia.; Laboratory of Plant Infectious Diseases, FRC Kazan Scientific Center of Russian Academy of Sciences, Kazan, Tatarstan 420111, Russia.
Sazykina M; Southern Federal University, Rostov-on-Don 344090, Russia.
Akylbekov N; Laboratory of Engineering Profile 'Physical and Chemical Methods of Analysis', Korkyt Ata Kyzylorda University, Kyzylorda 120014, Kazakhstan.
Gildebrant A; Southern Federal University, Rostov-on-Don 344090, Russia.
Sazykin I; Southern Federal University, Rostov-on-Don 344090, Russia.
Burilov A; Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Tatarstan 420088, Russia.; Laboratory of Plant Infectious Diseases, FRC Kazan Scientific Center of Russian Academy of Sciences, Kazan, Tatarstan 420111, Russia.
Appazov N; Laboratory of Engineering Profile 'Physical and Chemical Methods of Analysis', Korkyt Ata Kyzylorda University, Kyzylorda 120014, Kazakhstan.; I. Zhakaev Kazakh Scientific Research Institute of Rice Growing, Kyzylorda 120008, Kazakhstan.
Karchava S; Southern Federal University, Rostov-on-Don 344090, Russia.
Klimova M; Southern Federal University, Rostov-on-Don 344090, Russia.
Voloshina A; Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Tatarstan 420088, Russia.
Sapunova A; Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Tatarstan 420088, Russia.
Gumerova S; Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Tatarstan 420088, Russia.
Khamatgalimov A; Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Tatarstan 420088, Russia.
Gerasimova T; Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Tatarstan 420088, Russia.
Dobrynin A; Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center, Russian Academy of Sciences, Kazan, Tatarstan 420088, Russia.
Gogoleva O; Laboratory of Plant Infectious Diseases, FRC Kazan Scientific Center of Russian Academy of Sciences, Kazan, Tatarstan 420111, Russia.
Gorshkov V; Laboratory of Plant Infectious Diseases, FRC Kazan Scientific Center of Russian Academy of Sciences, Kazan, Tatarstan 420111, Russia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Nov 05; Vol. 21 (21). Date of Electronic Publication: 2020 Nov 05.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*/methods
Anti-Infective Agents/*chemical synthesis
Antineoplastic Agents/*chemical synthesis
Benzoxazoles/*chemical synthesis
Anti-Infective Agents/chemistry ; Anti-Infective Agents/pharmacology ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Benzoxazoles/chemistry ; Dose-Response Relationship, Drug ; Drug Design ; Drug Screening Assays, Antitumor ; Drugs, Investigational/chemical synthesis ; Drugs, Investigational/chemistry ; HeLa Cells ; Humans ; Inhibitory Concentration 50 ; MCF-7 Cells ; Microbial Sensitivity Tests ; Molecular Structure ; Structure-Activity Relationship ; Tumor Cells, Cultured
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
New Hybrids of 4-Amino-2,3-polymethylene-quinoline and p -Tolylsulfonamide as Dual Inhibitors of Acetyl- and Butyrylcholinesterase and Potential Multifunctional Agents for Alzheimer's Disease Treatment.
Autorzy:
Makhaeva GF; Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Kovaleva NV; Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Boltneva NP; Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Lushchekina SV; Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia.; Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.
Astakhova TY; Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.
Rudakova EV; Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Proshin AN; Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Serkov IV; Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Radchenko EV; Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia.; Department of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Palyulin VA; Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia.; Department of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Bachurin SO; Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
Richardson RJ; Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI 48109, USA.; Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.; Center of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2020 Aug 27; Vol. 25 (17). Date of Electronic Publication: 2020 Aug 27.
Typ publikacji:
Journal Article
MeSH Terms:
Antioxidants*/chemical synthesis
Antioxidants*/chemistry
Cholinesterase Inhibitors*/chemical synthesis
Cholinesterase Inhibitors*/chemistry
Drug Discovery*
Quinolines*/chemical synthesis
Quinolines*/chemistry
Sulfonamides*/chemical synthesis
Sulfonamides*/chemistry
Alzheimer Disease/drug therapy ; Drug Interactions ; Humans ; Models, Molecular ; Structure-Activity Relationship
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Peptide Therapeutics 2.0.
Autorzy:
de la Torre BG; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa.
Albericio F; Peptide Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Westville, Durban 4000, South Africa.; CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain.; Department of Organic Chemistry, University of Barcelona, Martí i Franqués 1-11, 08028 Barcelona, Spain.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2020 May 13; Vol. 25 (10). Date of Electronic Publication: 2020 May 13.
Typ publikacji:
Editorial
MeSH Terms:
Drug Discovery*
Drug Industry*
Peptides*/chemical synthesis
Peptides*/chemistry
Peptides*/therapeutic use
Humans
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Drug Syntheses Beyond the Rule of 5.
Autorzy:
Tyagi M; Department of Chemistry-BMC, Uppsala University, Box 576, 75123, Uppsala, Sweden.
Begnini F; Department of Chemistry-BMC, Uppsala University, Box 576, 75123, Uppsala, Sweden.
Poongavanam V; Department of Chemistry-BMC, Uppsala University, Box 576, 75123, Uppsala, Sweden.
Doak BC; Department of Medicinal Chemistry, MIPS, Monash University, 381 Royal Parade, Parkville, Victoria, 3052, Australia.
Kihlberg J; Department of Chemistry-BMC, Uppsala University, Box 576, 75123, Uppsala, Sweden.
Pokaż więcej
Źródło:
Chemistry (Weinheim an der Bergstrasse, Germany) [Chemistry] 2020 Jan 02; Vol. 26 (1), pp. 49-88. Date of Electronic Publication: 2019 Oct 11.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Drug Discovery*
Pharmaceutical Preparations/*chemical synthesis
Bacterial Proteins/chemistry ; Bacterial Proteins/metabolism ; Binding Sites ; Hepacivirus/enzymology ; Macrocyclic Compounds/chemical synthesis ; Macrocyclic Compounds/chemistry ; Macrocyclic Compounds/metabolism ; Peptidomimetics ; Pharmaceutical Preparations/chemistry ; Pharmaceutical Preparations/metabolism ; Protease Inhibitors/chemical synthesis ; Protease Inhibitors/chemistry ; Protease Inhibitors/metabolism ; Ribosomes/chemistry ; Ribosomes/metabolism ; Viral Proteins/chemistry ; Viral Proteins/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
Autorzy:
Sharma C; College of Pharmacy, Keimyung University, Daegu 42601, Korea.
Oh YJ; College of Pharmacy, Keimyung University, Daegu 42601, Korea.
Park B; College of Pharmacy, Keimyung University, Daegu 42601, Korea.
Lee S; College of Pharmacy, Keimyung University, Daegu 42601, Korea.
Jeong CH; College of Pharmacy, Keimyung University, Daegu 42601, Korea.
Lee S; College of Pharmacy, Keimyung University, Daegu 42601, Korea.
Seo JH; Department of Biochemistry, School of Medicine, Keimyung University, Daegu 42601, Korea.
Seo YH; College of Pharmacy, Keimyung University, Daegu 42601, Korea.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2019 Dec 09; Vol. 20 (24). Date of Electronic Publication: 2019 Dec 09.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Histone Deacetylase Inhibitors*/chemical synthesis
Histone Deacetylase Inhibitors*/chemistry
Histone Deacetylase Inhibitors*/pharmacology
Thiazolidinediones*/chemical synthesis
Thiazolidinediones*/chemistry
Thiazolidinediones*/pharmacology
Histone Deacetylase 6/*antagonists & inhibitors
Amphetamine-Related Disorders/drug therapy ; Amphetamine-Related Disorders/enzymology ; Cell Line, Tumor ; Histone Deacetylase 6/chemistry ; Histone Deacetylase 6/metabolism ; Humans ; Isoenzymes/antagonists & inhibitors ; Isoenzymes/chemistry ; Isoenzymes/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery of 8-Amino-Substituted 2-Phenyl-2,7-Naphthyridinone Derivatives as New c-Kit/VEGFR-2 Kinase Inhibitors.
Autorzy:
Sun H; Nanjing Polytechnic Institute, Nanjing 210048, China.
Zhuo L; Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Dong H; Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Huang W; Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, China.
She N; Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2019 Dec 05; Vol. 24 (24). Date of Electronic Publication: 2019 Dec 05.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Molecular Docking Simulation*
Protein Kinase Inhibitors*/chemical synthesis
Protein Kinase Inhibitors*/chemistry
Proto-Oncogene Proteins c-kit*/antagonists & inhibitors
Proto-Oncogene Proteins c-kit*/chemistry
Vascular Endothelial Growth Factor Receptor-2*/antagonists & inhibitors
Vascular Endothelial Growth Factor Receptor-2*/chemistry
Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
CNSL, a Promising Building Blocks for Sustainable Molecular Design of Surfactants: A Critical Review.
Autorzy:
Roy A; Orpia Innovation, CNRS, Bâtiment Chimie Balard, 1919 Route de Mendes, 34000 Montpellier, France.
Fajardie P; Institut Charles Gerhardt Montpellier (ICGM), Université de Montpellier, CNRS, ENSCM, 34095 Montpellier, France.
Lepoittevin B; Laboratoire de Chimie Moléculaire et Thio-Organique (LCMT), Normandie Université, ENSICAEN, UNICAEN, UMR CNRS 6507, 6 Boulevard Maréchal Juin, 14050 Caen, France.
Baudoux J; Laboratoire de Chimie Moléculaire et Thio-Organique (LCMT), Normandie Université, ENSICAEN, UNICAEN, UMR CNRS 6507, 6 Boulevard Maréchal Juin, 14050 Caen, France.
Lapinte V; Institut Charles Gerhardt Montpellier (ICGM), Université de Montpellier, CNRS, ENSCM, 34095 Montpellier, France.
Caillol S; Institut Charles Gerhardt Montpellier (ICGM), Université de Montpellier, CNRS, ENSCM, 34095 Montpellier, France.
Briou B; Orpia Innovation, CNRS, Bâtiment Chimie Balard, 1919 Route de Mendes, 34000 Montpellier, France.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2022 Feb 21; Vol. 27 (4). Date of Electronic Publication: 2022 Feb 21.
Typ publikacji:
Journal Article; Meta-Analysis; Review
MeSH Terms:
Drug Design*
Drug Discovery/*methods
Surface-Active Agents/*chemistry
Chemistry Techniques, Synthetic ; Green Chemistry Technology ; Humans ; Molecular Structure ; Structure-Activity Relationship ; Surface-Active Agents/chemical synthesis ; Surface-Active Agents/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pyrazine and Phenazine Heterocycles: Platforms for Total Synthesis and Drug Discovery.
Autorzy:
Huigens RW 3rd; Center for Natural Products, Drug Discovery and Development (CNPD3), Department of Medicinal Chemistry, University of Florida, 1345 Center Drive, Gainesville, FL 32610, USA.
Brummel BR; Center for Natural Products, Drug Discovery and Development (CNPD3), Department of Medicinal Chemistry, University of Florida, 1345 Center Drive, Gainesville, FL 32610, USA.
Tenneti S; Center for Natural Products, Drug Discovery and Development (CNPD3), Department of Medicinal Chemistry, University of Florida, 1345 Center Drive, Gainesville, FL 32610, USA.
Garrison AT; Center for Natural Products, Drug Discovery and Development (CNPD3), Department of Medicinal Chemistry, University of Florida, 1345 Center Drive, Gainesville, FL 32610, USA.
Xiao T; Center for Natural Products, Drug Discovery and Development (CNPD3), Department of Medicinal Chemistry, University of Florida, 1345 Center Drive, Gainesville, FL 32610, USA.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2022 Feb 07; Vol. 27 (3). Date of Electronic Publication: 2022 Feb 07.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Chemistry, Pharmaceutical*
Drug Discovery/*methods
Heterocyclic Compounds/*chemical synthesis
Phenazines/*chemistry
Pyrazines/*chemistry
Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect.
Autorzy:
Ibrahim TS; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Hawwas MM; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
Malebari AM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Taher ES; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
Omar AM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Neamatallah T; Department of Pharmacology and toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Abdel-Samii ZK; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Safo MK; Institute for Structural Biology, Drug Discovery and Development, Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.
Elshaier YAMM; Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City, Menoufia, Egypt.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2021 Dec; Vol. 36 (1), pp. 802-818.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Quinolines/*pharmacology
Stilbenes/*pharmacology
Tubulin/*metabolism
Tubulin Modulators/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Membrane Potential, Mitochondrial/drug effects ; Polymerization/drug effects ; Quinolines/chemical synthesis ; Quinolines/chemistry ; Reactive Oxygen Species/metabolism ; Stilbenes/chemical synthesis ; Stilbenes/chemistry ; Structure-Activity Relationship ; Tubulin Modulators/chemical synthesis ; Tubulin Modulators/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3- a :3',4'- c ]quinoxaline derivatives as anticancer agents and apoptosis inducers.
Autorzy:
Alsaif NA; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Taghour MS; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Alanazi MM; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Obaidullah AJ; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Al-Mehizia AA; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Alanazi MM; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Aldawas S; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Elwan A; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Elkady H; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2021 Dec; Vol. 36 (1), pp. 1093-1114.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Discovery*
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Protein Kinase Inhibitors/*pharmacology
Quinoxalines/*pharmacology
Vascular Endothelial Growth Factor Receptor-2/*antagonists & inhibitors
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Quinoxalines/chemical synthesis ; Quinoxalines/chemistry ; Structure-Activity Relationship ; Vascular Endothelial Growth Factor Receptor-2/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 389

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies